We help our customers to deal with challenging recombinant proteins related projects. To see some solved ones, please provide us with your name and email address. We will be happy to send you selected case studies presentation showcasing our competences. Maybe issues you are facing now, are already described there...
Therapeutic medical device for the treatment of NMO (Neuromyelitis Optica)
AptaPheresis – development of a first-in-class therapeutic medical device for the treatment of an autoimmune neurodegenerative disorder - NMO (Neuromyelitis Optica)
Autoimmune myelitis and optic neuritis termed NMO (Neuromyelitis Optica) is a neurodegenerative disease characterized by a dramatic and worsening clinical course. Most patients have the recurrent form of the disease, with the remission period in a range from a few weeks to a few months. Not infrequently, tetraplegia and complete vision loss develops in a very short period of time. Unfortunately, in some cases the disease ends in patient’s death due to respiratory muscle paralysis.
Despite the fact that NMO is classified as an orphan disease, it is estimated that over 300 000 people suffer from it worldwide. Currently, there is no effective and safe treatment available.
A new medical device, being developed within this project, will be used for therapeutic apheresis during which specific pathological factors responsible for NMO will be selectively removed from the patient’s blood. All other blood components will stay intact which will significantly eliminate adverse effects of such a therapy. The product has therefore a very high potential to become the best and only chance of the patients for a good recovery.